Grant of options
London, UK - 24 November 2023: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, announces that on 23 November 2023 nil-cost share options over Ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").
2023 LTIP Awards
| Name of individual | Title | Number of shares subject to the 2023 LTIP award | Total shares over which options now held | Percentage of current issued share capital under option |
| Thierry Cournez | Chief Operating Officer | 66,437 | 66,437 | 0.069% |
The LTIP awards are subject to performance conditions. As set out in the 2022 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2023, 2024 and 2025) and strategic milestones (20% of the award).
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Thierry Cournez | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Operating Officer
| ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. | ||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
| ||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 66,437 shares in total
N/A
| ||||
| e) | Date of the transaction | 2023-11-23 | ||||
| f) | Place of the transaction | Outside of trading venue | ||||
-Ends-
| For further information, please contact: | |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
